Molecular Templates Inc (OQ:MTEM)

Apr 09, 2024 08:11 am ET
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activi
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Mar 29, 2024 08:21 am ET
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Mar 28, 2024 08:11 am ET
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to...
Mar 04, 2024 08:11 am ET
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Feb 08, 2024 05:55 pm ET
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the...
Nov 13, 2023 04:11 pm ET
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Nov 02, 2023 04:11 pm ET
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first...
Nov 01, 2023 04:12 pm ET
Molecular Templates to Participate in Upcoming Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create...
Sep 28, 2023 04:11 pm ET
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of...
Aug 11, 2023 11:22 am ET
Molecular Templates Announces 1-for-15 Reverse Stock Split
Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the Board and stockholders of the...
Aug 10, 2023 08:08 am ET
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Aug 02, 2023 04:11 pm ET
Molecular Templates Announces Executive Leadership Changes
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management...
Jul 13, 2023 08:14 am ET
Molecular Templates Announces Up to $40 Million Private Placement Offering
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Jun 16, 2023 08:56 pm ET
Molecular Templates Announces Debt Payoff and Restructuring
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Jun 01, 2023 07:57 am ET
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
May 26, 2023 05:10 pm ET
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
May 15, 2023 04:13 pm ET
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Apr 07, 2023 06:50 pm ET
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (the “FDA”) informed MTEM that it has placed a partial clinical hold on the Phase 1 study of MT-0169 based on...
Mar 30, 2023 06:10 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Mar 09, 2023 10:02 am ET
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to...
Mar 01, 2023 04:44 pm ET
Molecular Templates Announces Participation in Upcoming Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create...
Dec 02, 2022 05:02 pm ET
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual M
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Nov 23, 2022 04:30 pm ET
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Nov 10, 2022 04:15 pm ET
Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create...
Nov 04, 2022 11:00 am ET
Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Aug 31, 2022 04:51 pm ET
Molecular Templates Announces Participation in Four Upcoming Conferences
Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will...
Aug 11, 2022 04:10 pm ET
Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create...
Jun 06, 2022 08:00 am ET
Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs
Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
May 17, 2022 04:05 pm ET
Molecular Templates to Present at Upcoming Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will...
May 12, 2022 04:30 pm ET
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Apr 12, 2022 07:30 am ET
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach
Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), reviews...
Apr 08, 2022 08:00 am ET
Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies...
Mar 28, 2022 04:30 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Mar 02, 2022 08:00 am ET
Molecular Templates Strengthens Board of Directors and Management Team
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies...
Mar 01, 2022 08:00 am ET
Molecular Templates to Present at the Upcoming Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 30, 2021 05:30 pm ET
Molecular Templates Provides Corporate Update and Outlines 2022 Milestones
Molecular Templates, Inc.(Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies...
Nov 18, 2021 08:00 am ET
Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Nov 15, 2021 07:30 am ET
Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Sep 20, 2021 08:00 am ET
Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted,...
Aug 12, 2021 04:30 pm ET
Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Jul 09, 2021 08:00 am ET
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Jul 06, 2021 08:00 am ET
Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted,...
Jun 30, 2021 08:30 am ET
Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders,...
May 13, 2021 04:30 pm ET
Molecular Templates, Inc. Reports First Quarter 2021 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Apr 12, 2021 07:00 am ET
Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Apr 05, 2021 07:00 am ET
Molecular Templates to Prioritize Next-Generation ETB Candidates
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Mar 18, 2021 04:30 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today...
Feb 26, 2021 08:00 am ET
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Feb 18, 2021 07:30 am ET
Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Feb 17, 2021 04:05 pm ET
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Feb 11, 2021 07:30 am ET
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer
Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that it has entered into a worldwide strategic research collaboration with Bristol Myers Squibb to discover and develop multiple novel therapies designed for...
Jan 19, 2021 08:00 am ET
Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies...
Dec 21, 2020 04:30 pm ET
Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies...
Nov 30, 2020 09:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM
Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Nov 25, 2020 10:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM
Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Nov 21, 2020 11:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM
Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Nov 16, 2020 09:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM
Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Nov 16, 2020 04:30 pm ET
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 05, 2020 04:30 pm ET
Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies...
Sep 23, 2020 07:00 am ET
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date,...
Sep 03, 2020 08:00 am ET
Molecular Templates to Participate in September Virtual Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Aug 06, 2020 04:30 pm ET
Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies...
Jul 20, 2020 04:30 pm ET
Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered...
Jun 22, 2020 07:30 am ET
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered...
May 22, 2020 08:00 am ET
Molecular Templates, Inc. Announces $45 Million Debt Financing From K2 HealthVentures
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered...
May 15, 2020 07:00 am ET
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies...
May 13, 2020 04:30 pm ET
Molecular Templates to Participate in Two May Virtual Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
May 11, 2020 04:30 pm ET
Molecular Templates, Inc. Reports First Quarter 2020 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies...
May 07, 2020 04:30 pm ET
Molecular Templates, Inc. Announces that the 2020 Annual Meeting of Stockholders Will be Held in Virtual Format
Molecular Templates, Inc. (the “Company”) (Nasdaq: MTEM) announced today that the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually due to the public health impact of the novel coronavirus outbreak (COVID-19) and to...
Mar 12, 2020 04:30 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies...
Feb 28, 2020 08:00 am ET
Molecular Templates to Present at Three March Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Feb 19, 2020 07:00 am ET
Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple Myeloma
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Jan 08, 2020 08:00 am ET
Molecular Templates Provides Corporate Update and Outlines 2020 Milestones
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), provided a corporate update...
Dec 19, 2019 07:00 am ET
Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics,...
Dec 09, 2019 10:00 am ET
Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics,...
Nov 26, 2019 08:00 am ET
Molecular Templates to Present at Two December Investor Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
Nov 21, 2019 07:00 am ET
Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 20, 2019 04:01 pm ET
Molecular Templates, Inc. Announces Proposed Public Equity Offering
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 18, 2019 07:00 am ET
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop...
Nov 14, 2019 08:00 am ET
Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111
Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with its partner Molecular Templates (Nasdaq: MTEM). This Phase I first-in-human...
Nov 12, 2019 05:00 pm ET
Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are...
Nov 07, 2019 04:27 pm ET
Molecular Templates Hosting Analyst & Investor Meeting
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for...
Sep 23, 2019 04:30 pm ET
Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for...
Aug 12, 2019 04:30 pm ET
Molecular Templates, Inc. Reports Second Quarter 2019 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are...
Jun 17, 2019 08:00 am ET
Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38
Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic...
May 14, 2019 04:30 pm ET
Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
May 13, 2019 04:01 pm ET
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Apr 25, 2019 10:12 am ET
The Judge Group Named a Winner of the Delaware Valley 2019 Top Workplaces Award by Philadelphia Media Network
The Judge Group, a leading global professional services firm, has been awarded a 2019 Top Workplaces honor by Philadelphia Media Network. The award is based solely on employee feedback gathered through a third-party survey administered by research...
Apr 22, 2019 08:00 am ET
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Apr 10, 2019 09:10 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Cousins Properties, Versum Materials, Meritor, Ardelyx, Molecular Templates, and Talend S.A — New Research Emphasizes Economic Growt
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cousins Properties Incorporated (NYSE:CUZ), Versum Materials Inc. (NYSE:VSM),...
Apr 02, 2019 07:00 am ET
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2019 Highlight Evolution of ETB Platform
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Mar 28, 2019 04:30 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Mar 28, 2019 08:00 am ET
Molecular Templates Announces Initiation of Phase II Monotherapy Study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Mar 05, 2019 04:30 pm ET
Molecular Templates to Present a Corporate Overview at the Cowen & Company 39th Annual and the Oppenheimer & Co. 29th Annual Health Care Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Feb 27, 2019 05:00 pm ET
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2019
Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in...
Feb 19, 2019 04:30 pm ET
Molecular Templates Appoints Roger J. Waltzman, M.D., as Chief Medical Officer
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Feb 12, 2019 08:30 am ET
New Research Coverage Highlights Overstock, Regeneron Pharmaceuticals, Molecular Templates, The Ensign Group, Limoneira, and Primo Water — Consolidated Revenues, Company Growth, and Expectations for 2
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Overstock.com, Inc. (NASDAQ:OSTK), Regeneron Pharmaceuticals, Inc....
Nov 26, 2018 04:30 pm ET
Molecular Templates to Present at the Evercore ISI and BMO Healthcare Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Nov 13, 2018 04:30 pm ET
Molecular Templates, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Nov 09, 2018 08:00 am ET
Study on Molecular Templates’ PD-L1 ETB with Antigen Seeding Technology Presented at SITC Annual Meeting
Molecular Templates, Inc., (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Oct 16, 2018 07:35 am ET
New Research Coverage Highlights Amtech, Neos Therapeutics, FTD Companies, John B. Sanfilippo & Son, Molecular Templates, and Aevi Genomic Medicine — Consolidated Revenues, Company Growth, and Expecta
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amtech Systems, Inc. (NASDAQ:ASYS), Neos Therapeutics, Inc. (NASDAQ:NEOS),...
Sep 26, 2018 08:00 am ET
Molecular Templates to Present at the Ladenburg Thalmann and Cantor Healthcare Conferences
Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Sep 25, 2018 04:30 pm ET
Molecular Templates, Inc. Announces Closing of Public Offering of Common Stock and the Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Sep 20, 2018 08:41 pm ET
Molecular Templates, Inc. Announces Pricing of Public Offering of Common Stock
Molecular Templates, Inc. (Nasdaq: MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer,...
Sep 19, 2018 04:01 pm ET
Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock
Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage oncology company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic...
Sep 19, 2018 08:00 am ET
Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy
Molecular Templates, Inc. (Nasdaq:MTEM) today announced an agreement with Takeda Pharmaceutical Company Limited (Takeda) for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as...
Aug 16, 2018 07:40 am ET
Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, a
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quanex Building Products Corporation (NYSE:NX), Molecular Templates Inc....
Aug 09, 2018 04:30 pm ET
Molecular Templates, Inc. Reports Second Quarter 2018 Financial Results
Molecular Templates, Inc. (Nasdaq:MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated,...
Jun 21, 2018 04:30 pm ET
Molecular Templates Set to Join the Russell 3000® and Russell Microcap® Indexes
Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in...
Jun 04, 2018 04:30 pm ET
Molecular Templates Presents Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018
Molecular Templates, Inc. (Nasdaq:MTEM), a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in...
May 31, 2018 04:05 pm ET
Molecular Templates to Present at the Jefferies Global Healthcare Conference
Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
May 23, 2018 08:15 am ET
Report: Exploring Fundamental Drivers Behind Tenneco, RadNet, Data I/O, Icahn Enterprises, PBF Logistics LP, and Molecular Templates — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tenneco Inc. (NYSE:TEN), RadNet, Inc. (NASDAQ:RDNT), Data I/O Corporation...
May 16, 2018 05:00 pm ET
Molecular Templates to Present Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018
Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in...
May 15, 2018 04:30 pm ET
Molecular Templates to Present at the UBS Global Healthcare Conference
Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
May 14, 2018 04:30 pm ET
Molecular Templates, Inc. Reports First Quarter 2018 Financial Results
Molecular Templates, Inc. (Nasdaq:MTEM) (“Molecular”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics...
Mar 30, 2018 08:25 am ET
Consolidated Research: 2018 Summary Expectations for RadNet, Molecular Templates, Federated Investors, Kadant, Heartland Financial, and Calyxt — Fundamental Analysis, Key Performance Indications
NEW YORK, March 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RadNet, Inc. (NASDAQ:RDNT), Molecular Templates Inc....
Mar 28, 2018 04:30 pm ET
Molecular Templates, Inc. Reports Fourth Quarter 2017 Financial Results
Update on MT-3724 Provided at World ADC Conference; More Data Expected in 2Q18
Mar 19, 2018 04:01 pm ET
Molecular Templates to Present at the Oppenheimer 28th Annual Healthcare Conference
AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Mar 15, 2018 08:00 am ET
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2018
Presentations will feature data on 1) the company’s Antigen Seeding Technology (AST) platform, and 2) MT-5111, an Engineered Toxin Body with a novel MOA against HER2 positive cancers
Mar 08, 2018 08:00 am ET
Molecular Templates to Present at the Cowen and Company 38th Annual Health Care Conference
AUSTIN, Texas, March 08, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Mar 02, 2018 04:30 pm ET
Molecular Templates Closes $10 Million Debt Facility with Perceptive Advisors
AUSTIN, Texas, March 02, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Jan 30, 2018 07:45 am ET
New Research: Key Drivers of Growth for Fidus Investment, Athenex, Threshold Pharmaceuticals, Cintas, GNC, and Hillenbrand — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fidus Investment Corporation (NASDAQ:FDUS), Athenex, Inc....
Jan 05, 2018 08:00 am ET
Molecular Templates Provides Corporate Update and Outlines 2018 Milestones
Takeda Nominated Two Targets Under Research Collaboration in Dec. 2017
Nov 21, 2017 04:01 pm ET
Molecular Templates to Present at the 29th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique...
Nov 14, 2017 04:15 pm ET
Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer
Company Also Added Key Members to the Senior Management Team
Nov 14, 2017 04:01 pm ET
Molecular Templates, Inc. Reports Third Quarter 2017 Financial Results
Completed Merger with Threshold Pharmaceuticals in August
Aug 14, 2017 08:00 am ET
Molecular Templates to Present at the 2017 Wedbush PacGrow Healthcare Conference
AUSTIN, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the 2017 Wedbush PacGrow Healthcare Conference, taking place August 15-16 at the Le Parker Meridien hotel in New York City....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More